Mohit Manrao/LinkedIn
May 28, 2025, 09:58
Mohit Manrao: AstraZeneca will share trial results from SERENA-6, MATTERHORN and DESTINY-Breast09 at ASCO 2025
Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“This post is intended for a US audience
ASCO 2025 is on the horizon and AstraZeneca is ready to make history again! We’ll be taking the plenary stage for the 7th year in a row, this time with TWO plenary sessions and a late-breaker, along with a full slate of study readouts.
We are gearing up to share:
– SERENA-6 Phase III trial for 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer with an emergent ESR1 tumor mutation.
– MATTERHORN Phase III trial in resectable early-stage gastric and gastroesophageal junction cancers.
– DESTINY-Breast09 Phase III trial for 1st-line HER2-positive metastatic breast cancer.
But wait…there’s more! We’re showing up with more than 80 abstracts across our approved medicines and pipeline molecules – with new data in lung, liver, bladder and blood cancers. Every discovery means we can accelerate beyond the possible, redefining care and transforming outcomes for patients facing their toughest battles.
We believe our approach will ultimately eliminate cancer as a cause of death. ASCO kicks off on May 31 and I can’t wait to fill you in on how we’re pushing the boundaries of science.
Read more about what we’re planning for ASCO 2025.”
More posts featuring Mohit Manrao on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11
May 29, 2025, 12:46
May 29, 2025, 12:43